All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer
Executive Summary
Maturing data supporting first-line indications for Merck’s Keytruda, Bristol’s Opdivo and BeiGene’s Tevimbra show inadequate efficacy for patients at the lowest level of PD-L1 expression in esophageal and gastric cancers.